AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38164441
Drug: FUEL intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FUEL intervention consisting of weekly online lectures and individual athlete-centered nutrition counseling every other week for sixteen weeks.
Trial: 38164586
Drug: Radioligand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand therapy agent (specific agent not mentioned)
Trial: 38164752
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard blood pressure treatment)
Trial: 38164757
Drug: XTX101 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XTX101 monotherapy
Trial: 38164757
Drug: XTX101 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XTX101 in combination with anti-PD-1 mAb
Trial: 38165016
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) treatment combined with zoledronic acid (ZA)
Trial: 38165027
Drug: m-health tool
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-health tool (pre-programmed tablet with weighing scale and interactive education about HF self-care)
Trial: 38165333
Drug: IV nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV nipocalimab 5 mg/kg Q4W
Trial: 38165333
Drug: IV nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV nipocalimab 30 mg/kg Q4W
Trial: 38165333
Drug: IV nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV nipocalimab 60 mg/kg Q2W
Trial: 38165333
Drug: IV nipocalimab
RxNorm normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV nipocalimab 60 mg/kg single dose
Trial: 38165683
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel with bevacizumab (Cohort 1A)
Trial: 38165683
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel without bevacizumab (Cohort 1B)
Trial: 38165683
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa 2,400 mg every 3 weeks plus cisplatin plus radiation, followed by bintrafusp alfa monotherapy maintenance (Cohort 2)
Trial: 38166187
Drug: Quantum molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quantum molecular resonance treatment with Rexon-Eye device, once per week for 4 weeks
Trial: 38166598
Drug: Emergence agitation
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergence agitation and high-dose opioid consumption
Trial: 38166647
Drug: Regorafenib monotherapy
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib monotherapy
Trial: 38166647
Drug: Regorafenib combined
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib combined with immune-checkpoint inhibitors
Trial: 38166710
Drug: Levetiracetam 1000
RxNorm normalized name: levetiracetam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 1000 mg IV every 12 hours
Trial: 38166913
Drug: Acetazolamide (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (twice daily, 2 days)
Trial: 38166913
Drug: Rapid-Ripc (RIPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-Ripc (RIPC four times daily, 3 days)
Trial: 38166913
Drug: Ripc (RIPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ripc (RIPC twice daily, 6 days)
Trial: 38167019
Drug: Adalimumab with
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab with methotrexate co-treatment
Trial: 38167022
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radiomics features and serum β-D-glucan levels
Trial: 38167064
Drug: 5% losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% losartan potassium loaded in ethosomal gel
Trial: 38167064
Drug: 10% triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% triamcinolone acetonide (intralesional injections)
Trial: 38167115
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) administered via continuous intravenous administration for 7 days
Trial: 38167115
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) administered via continuous intravenous administration for 7 days
Trial: 38167178
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS (60 min duration, placebo treatment for 10 sessions)
Trial: 38167204
Drug: Hypnotic suggestion
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestion intervention group receiving four weekly 1-h sessions with induction and hypnosis
Trial: 38167204
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control group receiving four weekly 1-h sessions of induction and mindfulness
Trial: 38167503
Drug: Immunotherapy (ipilimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (ipilimumab plus nivolumab) followed by BRAF/MEK inhibition (encorafenib plus binimetinib)
Trial: 38167503
Drug: 8-week induction
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week induction course of targeted therapy (encorafenib plus binimetinib) followed by immunotherapy
Trial: 38167503
Drug: Immunotherapy (ipilimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (ipilimumab plus nivolumab)
Trial: 38167806
Drug: Chemotherapy SAP
RxNorm normalized name: Bambusa vulgaris sap extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy SAP alone (SAP)
Trial: 38167882
Drug: Bipolar androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar androgen therapy (BAT) with nivolumab
Trial: 38167937
Drug: Chemotherapy (SOX/XELOX)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (SOX/XELOX)
Trial: 38168442
Drug: 5% 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-Fluorouracil (5-FU) cream, 2g self-administered intravaginally every other week for eight applications.
Trial: 38169574
Drug: Low-dose QiShen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose QiShen YiQi Dripping Pills (QSYQ)
Trial: 38169574
Drug: High-dose QiShen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose QiShen YiQi Dripping Pills (QSYQ)
Trial: 38169790
Drug: SW-BIC-213 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SW-BIC-213 (25 μg)
Trial: 38170033
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg twice daily with ASA 80 mg once daily
Trial: 38170033
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg once daily with ASA 80 mg once daily
Trial: 38170185
Drug: Ketamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine treatment (dosage and duration not available)
Trial: 38170256
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium valproate (SV) applied twice daily
Trial: 38170256
Drug: Topical mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mometasone furoate lotion applied twice daily
Trial: 38170256
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium valproate (SV) and topical steroids
Trial: 38170741
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (INO) at a maximum tolerated dose (MTD) of 0.6 mg/m2, administered on day 1 of 28-day cycles.
Trial: 38171034
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of Ca-HMB with resistance training (3 sessions/week)
Trial: 38171633
Drug: Chronotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronotherapy in addition to Treatment as Usual (TAU)
Trial: 38171926
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy vectors and strategies for liver-targeting
Trial: 38171926
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy administration in a fibrotic liver
Trial: 38172458
Drug: Alveolar ridge
RxNorm normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alveolar ridge splitting (ARS) with guided bone regeneration (GBR) using simvastatin (SMV) gel mixed bone graft and a barrier membrane with simultaneous implant placement
Trial: 38172458
Drug: Guided bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided bone regeneration (GBR) without simvastatin (SMV) gel
Trial: 38172930
Drug: CDSS-OPTIMED intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDSS-OPTIMED intervention (software program providing weekly personalized medication recommendations)
Trial: 38174147
Drug: LCPT (Life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPT (Life cycle pharma tacrolimus) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight.
Trial: 38174564
Drug: Control (discontinue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (discontinue all antihypertensive agents)
Trial: 38174569
Drug: Asundexian 50
RxNorm normalized name: Asundexian
DrugBank: Asundexian (DB19088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asundexian 50 mg daily
Trial: 38175228
Drug: Adjuvant transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant transcranial direct current stimulation (tDCS) with intensive speech-language therapy for 3 weeks
Trial: 38175228
Drug: Intensive speech-language
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive speech-language therapy for 3 weeks
Trial: 38175251
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg phosphorus
Trial: 38175448
Drug: sTK1 activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sTK1 activity at end of treatment visit
Trial: 38175466
Drug: Cenegermin 20
RxNorm normalized name: CENEGERMIN 20 ug in 1 mL OPHTHALMIC SOLUTION/ DROPS [OXERVATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenegermin 20 mcg/ml, 1 drop in the affected eye(s) 6 times/day for 8 weeks
Trial: 38175488
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray administered in < 5 min after seizure start
Trial: 38175488
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray administered in ≥ 5 min after seizure start
Trial: 38175627
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fractionated stereotactic radiotherapy or whole-brain radiotherapy with pyrotinib (400 mg, once daily) and capecitabine (1000 mg/m2, twice daily, on days 1-14 of each 21-day cycle)
Trial: 38175669
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Endocrine Therapy (ET)
Trial: 38175669
Drug: CDK4/6-inhibitors +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6-inhibitors + Endocrine Therapy (ET)
Trial: 38175837
Drug: School-based mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based mass drug administration (MDA)
Trial: 38176228
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (BMT) involving antiplatelet agents, blood pressure control, and statins
Trial: 38176782
Drug: Mavacamten 5
RxNorm normalized name: mavacamten 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten 5 mg once daily
Trial: 38176857
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Amantadine and TMS for 6 weeks
Trial: 38176866
Drug: Oxygen-ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-ozone therapy 2-3 times a week for 6 weeks (maximum of 15 sessions) with oral antibiotic therapy
Trial: 38176866
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic therapy prescribed at baseline
Trial: 38176875
Drug: Exercise Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Therapy (ET) - 12-week rehabilitation programme
Trial: 38176875
Drug: Extracorporeal Shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shockwave Therapy (ESWT) - four sessions with 1 week rest between sessions during 1 month
Trial: 38177178
Drug: High aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High aspirin reaction unit (≥ 414)
Trial: 38177509
Drug: Rebound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebound therapy
Trial: 38177855
Drug: bidridistrogene xeboparvovec,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bidridistrogene xeboparvovec, an adeno-associated virus-based gene therapy
Trial: 38178048
Drug: Treatment modalities
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modalities for SE
Trial: 38178168
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and sufentanil in combination (P + S)
Trial: 38178168
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and esketamine in combination (P + K)
Trial: 38178168
Drug: Propofol and
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol and lidocaine in combination (P + L)
Trial: 38178223
Drug: Probiotics (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bifidobacterium lactis BI040, B. longum BL020, Lactobacillus rhamnosus LR110, L. casei LC130, L. acidophilus LA120, 5 billion CFU total)
Trial: 38178887
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) for acute basilar artery occlusion (BAO)
Trial: 38179936
Drug: Moderate low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Moderate low-dose radiotherapy, dosage and duration not available
Trial: 38181433
Drug: BMMNC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMMNC treatment
Trial: 38181724
Drug: Levcromakalim (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levcromakalim (0.05 mg/ml infusion)
Trial: 38181782
Drug: Intravenous high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high-dose methotrexate (MTX) 1.5 g/m2 after 6 cycles of R-CHOP regimen; IT liposomal cytarabine administered on day 0 of cycles 2 to 5 of R-CHOP; contralateral testis radiotherapy (25-30 Gy) recommended.
Trial: 38181795
Drug: serplulimab 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: serplulimab 4.5 mg/kg plus nab-paclitaxel and carboplatin
Trial: 38182456
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) with tPA
Trial: 38182456
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous thrombolysis (no IVT)
Trial: 38182784
Drug: Magnesium-Ibogaine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-Ibogaine therapy
Trial: 38182785
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg
Trial: 38182785
Drug: Ripretinib 150
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ripretinib 150 mg
Trial: 38183045
Drug: Neuromuscular joint-protective
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular joint-protective exercise therapy program
Trial: 38183497
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg intravenous preoperatively)
Trial: 38183497
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg in initial irrigation fluid)
Trial: 38183525
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) fixed dosing regimen (n=168)
Trial: 38183526
Drug: CTC 100
RxNorm normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC 100 mg (44 mg rac-tramadol hydrochloride/56 mg celecoxib; n=164)
Trial: 38183526
Drug: CTC 150
RxNorm normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC 150 mg (66 mg rac-tramadol hydrochloride/84 mg celecoxib; n=160)
Trial: 38183526
Drug: CTC 200
RxNorm normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC 200 mg (88 mg rac-tramadol hydrochloride/112 mg celecoxib; n=160)
Trial: 38183526
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg four times daily (n=159)
Trial: 38183526
Drug: Placebo four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo four times daily (n=83)
Trial: 38183804
Drug: Sham Quasi-Desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham Quasi-Desensitization Therapy for Insomnia (DTI)
Trial: 38184303
Drug: CMV-targeting T
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV-targeting T cell receptor-engineered T (CMV-TCR-T) cell therapy, administered in 1 to 3 doses.
Trial: 38184414
Drug: Preclinical model
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preclinical model with anti-PD-1 antibody
Trial: 38184559
Drug: Contextual factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contextual factors (e.g., COVID-19 pandemic)
Trial: 38184582
Drug: SGLT-2i/GLP-1RA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGLT-2i/GLP-1RA combination therapy
Trial: 38184633
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of smoking cessation interventions at outpatient OAT clinics, including weekly follow-up, a short behavioural intervention, and provision of nicotine replacement products.
Trial: 38185589
Drug: Sintilimab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab monotherapy
Trial: 38185589
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus platinum-based chemotherapy
Trial: 39536751
Drug: Pembrolizumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab plus platinum-based chemotherapy
Trial: 38185720
Drug: Treatment-naïve BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-naïve BC patients